Method for the prognosis of survival time of a patient suffering from a solid cancer
View Patent ↗The present invention relates to an in vitro method for the prognosis of survival of a patient suffering from a solid cancer, comprising the quantification of the cell density of CD8+ cells and DC-LAMP+ dendritic cells present in a tumor tissue sample from said patient, wherein a high density of CD8+ cells and DC-LAMP+ dendritic cells indicates that the patient has a favorable prognosis, a high density of CD8+ cells and a low density of DC-LAMP+ dendritic cells indicates that the patient has a poor prognosis, and a low density of CD8+ cells and DC-LAMP+ dendritic cells indicates that the patient has the worst prognosis.
1. A method for treating a patient suffering from a solid cancer containing tumor-induced lymphoid structures, wherein said method comprises the following steps:
a) quantifying, in a tumor tissue sample from said patient, the cell density of cluster of differentiation 8-positive (CD8+) cells;
b) quantifying, in a tumor-induced lymphoid structure from said patient, the cell density of dendritic cell-lysosomal associated membrane protein positive (DC-LAMP+) dendritic cells;
c) comparing cell density values obtained at step a) and b) with predetermined reference values for each type of cells at each location; and
d) providing the patient with an adjuvant therapy when each of the cell density of CD8+ cells and DC-LAMP+ dendritic cells are lower than said predetermined reference values.
2. The method of claim 1 , wherein the patient is a patient with stage I cancer.
3. The method of claim 1 , wherein the patient is a patient with stage II or III cancer.
4. The method of claim 1 , wherein the tumor tissue sample is selected from the group consisting of (i) a global primary tumor sample as a whole, (ii) a tumor nest sample, and (iii) a stroma sample of the whole tumor section.
5. The method of claim 4 , wherein the tumor tissue sample is in a stroma sample of the whole tumor section.
6. The method of claim 1 , wherein the solid cancer is a lung cancer, a colorectal cancer or a breast cancer.
7. The method of claim 6 , wherein the solid cancer is a lung cancer.
8. The method of claim 7 , wherein the solid cancer is a non-small cell lung cancer.
9. A method for treating a patient suffering from a solid cancer containing tumor-induced lymphoid structures, wherein said method comprises the following steps:
a) quantifying, in a tumor tissue sample from said patient, the cell density of CD8+ cells;
b) quantifying, in a tumor-induced lymphoid structure from said patient, the cell density of DC-LAMP+ dendritic cells;
c) comparing cell density values obtained at step a) and b) with predetermined reference values for each type of cells at each location; and
d) providing the patient with a cytotoxic agent when each of the cell density of CD8+ cells and DC-LAMP+ dendritic cells are lower than said predetermined reference values.
10. The method of claim 9 , wherein the patient is a patient with stage I cancer.
11. The method of claim 9 , wherein the patient is a patient with stage II or III cancer.
12. The method of claim 9 , wherein the tumor tissue sample is selected from the group consisting of (i) a global primary tumor sample as a whole, (ii) a tumor nest sample and (iii) a stroma sample of the whole tumor section.
13. The method of claim 12 , wherein the tumor tissue sample is a stroma sample of the whole tumor section.
14. The method of claim 9 , wherein the solid cancer is a lung cancer, a colorectal cancer or a breast cancer.
15. The method of claim 14 , wherein the solid cancer is a lung cancer.
16. The method of claim 15 , wherein the solid cancer is a non-small cell lung cancer.